Dasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent anti-leukemia cell activity

Dasatinib (DAS), a second-generation tyrosine kinase inhibitor, is highly effective in treating chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. However, its clinical use is limited due to serious adverse effects. DAS can disrupt endothelial barrier integri...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Chunling, Li, Bo, Li, Zhenyu, Shetty, Sreerama, Fu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226540/
https://www.ncbi.nlm.nih.gov/pubmed/27391073
http://dx.doi.org/10.18632/oncotarget.10435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226540/
https://www.ncbi.nlm.nih.gov/pubmed/27391073
http://dx.doi.org/10.18632/oncotarget.10435

Ejemplares similares